Postoperative mean logMAR BCVA at 1 year · participants/eyes with corneal endothelial failure
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Severe visual loss (LogMAR BCVA of 1.0 or more) within 12 months' · participants/eyes with corneal endothelial failure
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Endothelial cell count cells/mm2, 12 months' · participants/eyes with corneal endothelial failure
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Corneal graft rejection any time pointa · participants/eyes with corneal endothelial failure
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Primary graft failure any time pointa · participants/eyes with corneal endothelial failure
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Corneal graft dislocation any time pointa · participants/eyes with corneal endothelial failure
Descemet’s membrane endothelial keratoplasty (DMEK) may leads to higher corneal graft dislocation any time pointa compared with descemet’s stripping automated endothelial keratoplasty (DSAEK) (low certainty).
1 finding from 1 review
RR 5.4 [1.51, 19.27]
Studies not reported
Low
Intervention not reported
7‐methylxanthine · children with progressive myopia (36 studies, 6263 participants) in the analysis Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
7‐methyxanthine · children with progressive myopia (38 studies, 6525 participants in analyses) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU
It is very uncertain whether methotrexate changes proportion of participants with confirmed macular edema (lower… compared with mycophenolate (very low certainty).
1 finding from 1 review
Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU
Methotrexate probably leads to higher proportion of participants achieving steroid‐sparing control§… compared with mycophenolate (moderate certainty).
1 finding from 1 review
Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU
Methotrexate showed no clear difference in proportion of participants experiencing complications or requiring… compared with mycophenolate (low certainty).
1 finding from 1 review
Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU
Methotrexate probably leads to higher proportion of participants achieving control of inflammation§… compared with mycophenolate (moderate certainty).
1 finding from 1 review
Change in BCVA (lower logMAR indicate better vision) · NIIPPU
1 finding from 1 review
Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vision‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Adverse events · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 12 to 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.23 [2.36, 7.59]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate